Inhibrx to present Phase 2/3 HexAgon-HN study of ordastobart plus pembrolizumab at ESMO 2026
INBX•Inhibrx outlined planned oncology study presentations, including the primary analysis from the Phase 2 portion of HexAgon-HN on Oct. 25, 2026, at ESMO in Madrid.
1. Upcoming study presentations
Inhibrx said the primary analysis from the Phase 2 portion of HexAgon-HN will be presented Oct. 25, 2026, at ESMO in Madrid. Secondary efficacy outcomes from the Phase 2 ChonDRAgon study are scheduled for Oct. 29 at MSTS, with updated subgroup findings and progression-free survival planned for Nov. 20 at CTOS in Seoul. Early clinical results from an INBRX-109 combination study in Ewing sarcoma are scheduled for a Nov. 19 poster at CTOS.
